OncoNano Medicine Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Series B2

  • Latest Deal Amount
  • $10.1M

  • Investors
  • 7

OncoNano Medicine General Information

Description

Developer of a nanotechnology platform designed to improve the delivery and activation of cancer therapies in acidic tumor environments. The company offers an ultra pH-sensitive polymeric micelle system, which remains inactive in the bloodstream, enabling surgeons to treat advanced cancer patients to access safer and more effective treatment options with reduced side effects.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3060 Pegasus Park Drive
  • Suite 244
  • Dallas, TX 75247
  • United States
+1 (682)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 3060 Pegasus Park Drive
  • Suite 244
  • Dallas, TX 75247
  • United States
+1 (682)

OncoNano Medicine Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoNano Medicine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series B2) 01-Oct-2026 $10.1M Completed Clinical Trials - Phase 3
10. Later Stage VC (Series B) 03-Jun-2025 Completed Clinical Trials - Phase 3
9. Later Stage VC (Series B) 02-Nov-2021 Completed Clinical Trials - Phase 3
8. Later Stage VC (Series A) 04-Sep-2020 Completed Clinical Trials - Phase 3
7. Grant 20-Aug-2020 Completed Clinical Trials - Phase 3
6. Grant 27-Aug-2019 Completed Product Development
5. Grant 01-Jan-2018 Completed Startup
4. Grant 21-Sep-2017 Completed Startup
3. Grant 01-Jan-2016 $269K Completed Startup
2. Grant 01-Jan-2014 $6M Completed Startup
To view OncoNano Medicine’s complete valuation and funding history, request access »

OncoNano Medicine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B2
Series B Prime
Series B 57,727,822 $0.000100 6% $0.34 $0.34 1x $0.34 10.18%
Series A 42,471,030 $0.000100 6% $0.24 $0.24 1x $0.24 7.49%
To view OncoNano Medicine’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

OncoNano Medicine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a nanotechnology platform designed to improve the delivery and activation of cancer therapies in acidic tum
Drug Discovery
Dallas, TX
22 As of 2026

Framingham, MA
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoNano Medicine Competitors (2)

One of OncoNano Medicine’s 2 competitors is RootPath, a Venture Capital-Backed company based in Framingham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
RootPath Venture Capital-Backed Framingham, MA
TScan Therapeutics Formerly VC-backed Waltham, MA
You’re viewing 2 of 2 competitors. Get the full list »

OncoNano Medicine Patents

OncoNano Medicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026050709-A1 Methods of treating cancer with polyvalent sting activating compositions and pd-1 inhibitors Pending 29-Aug-2024
AU-2023371676-A1 Protonated ph responsive polymer encapsulation of bispecific antibodies and cytokines Pending 06-Nov-2022
EP-4611726-A2 Protonated ph responsive polymer encapsulation of bispecific antibodies and cytokines Pending 06-Nov-2022
EP-4611726-A4 Protonated ph responsive polymer encapsulation of bispecific antibodies and cytokines Pending 06-Nov-2022
US-20240165026-A1 Protonated ph responsive polymer encapsulation of bispecific antibodies and cytokines Pending 06-Nov-2022 A61K47/34
To view OncoNano Medicine’s complete patent history, request access »

OncoNano Medicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoNano Medicine Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Advantech Capital Partners PE/Buyout Minority
AG Collective Capital Venture Capital Minority
CKG Management Venture Capital Minority
Green Park & Golf Ventures Venture Capital Minority
Houston Angel Network Angel Group Minority
You’re viewing 5 of 7 investors. Get the full list »

OncoNano Medicine FAQs

  • When was OncoNano Medicine founded?

    OncoNano Medicine was founded in 2014.

  • Where is OncoNano Medicine headquartered?

    OncoNano Medicine is headquartered in Dallas, TX.

  • What is the size of OncoNano Medicine?

    OncoNano Medicine has 22 total employees.

  • What industry is OncoNano Medicine in?

    OncoNano Medicine’s primary industry is Drug Discovery.

  • Is OncoNano Medicine a private or public company?

    OncoNano Medicine is a Private company.

  • What is the current valuation of OncoNano Medicine?

    The current valuation of OncoNano Medicine is .

  • What is OncoNano Medicine’s current revenue?

    The current revenue for OncoNano Medicine is .

  • How much funding has OncoNano Medicine raised over time?

    OncoNano Medicine has raised $127M.

  • Who are OncoNano Medicine’s investors?

    Advantech Capital Partners, AG Collective Capital, CKG Management, Green Park & Golf Ventures, and Houston Angel Network are 5 of 7 investors who have invested in OncoNano Medicine.

  • Who are OncoNano Medicine’s competitors?

    RootPath and TScan Therapeutics are competitors of OncoNano Medicine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process